Thema: US74065P1012
PRLD, US74065P1012
stock-market-6287711_1920.jpg - Foto: THN
Prelude Therapeutics stock outlines three-program clinical strategy
Prelude Therapeutics stock is backed by a narrower pipeline focused on JAK2, KAT6A and mCALR. Clinical validation remains the key test.
ad-hoc-news.de, heute 03:00 Uhr
PRLD, US74065P1012
Prelude Therapeutics secures Lilly deal. Citizens targets ...
Phase 1 enrollment is scheduled for the fourth quarter of 2026. Citizens targets Prelude Therapeutics stock at USD 6.00 on October 14, 2026.
ad-hoc-news.de, 21.10.26 01:49 Uhr
PRLD, US74065P1012
H.C. Wainwright keeps USD 8.00 target for Prelude Therapeutics ...
Lilly supplies two drugs for PRT13722 Phase 1 combinations. For Prelude Therapeutics stock, FDA clearance supports fourth-quarter 2026 enrollment.
ad-hoc-news.de, 16.10.26 02:35 Uhr
PRLD, US74065P1012
Wainwright targets Prelude Therapeutics stock at USD 8.00 ...
Wainwright reiterated Buy on October 13, 2026 with a USD 8.00 target. Prelude Therapeutics stock enters a Phase 1 trial in fourth-quarter 2026.
ad-hoc-news.de, 14.10.26 03:03 Uhr
PRLD, US74065P1012
Prelude Therapeutics stock gains 2.72 percent as targets ...
Six analysts assign Prelude Therapeutics stock a Moderate Buy consensus and an average USD 8.75 target. Q2 2026 revenue reached USD 5.704 million.
ad-hoc-news.de, 07.10.26 02:50 Uhr
Prelude, Therapeutics
Prelude Therapeutics Secures FDA Clearance for Key Drug ...
